Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2023 | Real-world outcomes of brexu-cel in patients with R/R MCL

Nausheen Ahmed • 9 Jun 2023
EHA 2023
Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Brexucabtagene autoleucel CAR-T

Nausheen Ahmed, MD, University of Kansas Medical Center, Kansas City, MO, briefly comments on a study evaluating the real-world outcomes of patients with mantle cell lymphoma (MCL) treated with brexucabtagene autoleucel (brexu-cel). Dr Ahmed explains that the results were similar to what was observed in the ZUMA-2 trial (NCT02601313), with similar efficacy measures and no new safety signals. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Kite: consulting, BMS: advisory board

More from Nausheen Ahmed

Addressing disparities in access to CAR-T therapy for hematological malignancies 1:18
Addressing disparities in access to CAR-T therapy for hematological malignancies
Nausheen Ahmed • 9 Jun 2023
Outcomes of outpatient tisa-cel recipients with B-NHL 0:47
Outcomes of outpatient tisa-cel recipients with B-NHL
Nausheen Ahmed • 9 Jun 2023
Exploring the role of CAR-T therapy in MCL & impact of prior treatment with BTKi or bendamustine 1:06
Exploring the role of CAR-T therapy in MCL & impact of prior treatment with BTKi or bendamustine
Nausheen Ahmed • 9 Jun 2023
Survey on the evaluation and management of DLBCL following suboptimal response to CAR-T therapy 7:35
Survey on the evaluation and management of DLBCL following suboptimal response to CAR-T therapy
Nausheen Ahmed • 20 Feb 2023

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals